（文章来源：证券日报） 证券日报网讯 12月12日，金城医药在互动平台回答投资者提问时表示，目前公司经营情况正常。公司 深耕"医药化工、合成生物学、女性健康科技、高端抗感染、新型烟草"领域，形成了以五大领域为战略 支撑的整体发展布局。公司凭借着稳定优质的产品质量，在行业内拥有较好的口碑，像AE活性酯、头 孢他啶活性酯、谷胱甘肽原料药等，此外公司抗生素注射剂、口服剂以及妇科口服、外用制剂等产品也 以优秀的品质在各自的治疗领域发挥着重要作用。2025年，公司多项产品完成国内国际注册，产品更加 丰富，竞争力进一步提升。公司将不断加大市场开拓力度，积极拓展新客户、新市场，持续推动公司发 展和经营业绩的提升。 ...

Core Viewpoint - The company has established a comprehensive development layout supported by five strategic areas, focusing on pharmaceuticals, synthetic biology, women's health technology, high-end anti-infection, and new tobacco fields [2]. Company Overview - The company specializes in the pharmaceutical and chemical industry, with key products including a series of cephalosporin side-chain active esters, biopharmaceuticals, specialty raw materials, and various formulations [2]. - Major products include AE active esters, cephalosporin derivatives, glutathione, and various dosage forms such as oral, topical, and injectable products targeting anti-infection and women's health [2]. Financial Data and Indicators - The company does not require retrospective adjustments or restatements of previous annual accounting data [3]. - There are no significant discrepancies between the financial indicators disclosed in quarterly and semi-annual reports [4].